News & Updates

Show Multimedia Only

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

In the treatment of patients with chronic obstructive pulmonary disease (COPD), the investigational dual phosphodiesterase (PDE) 3 and 4 inhibitor TQC3721 helps improve lung function, according to a phase 2 PACER-II study.

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

16 hours ago

Fluvoxamine wins, metformin disappoints in long COVID fatigue

20 hours ago by

The antidepressant fluvoxamine reduces long COVID fatigue, whereas the antidiabetic agent metformin fails to outperform placebo in the randomized REVIVE-TOGETHER trial.

Fluvoxamine wins, metformin disappoints in long COVID fatigue

20 hours ago

Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients

a day ago by

In older or frail patients with stage III non-small cell lung cancer (NSCLC), undergoing reduced radiotherapy (RT) followed by sequential chemo-immunotherapy results in survival outcomes similar to standard RT, indicating its utility in vulnerable populations, suggests a study.

Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients

a day ago

Adjuvant nivolumab confers no DFS benefit in resected NSCLC

17 Jun 2026

In the treatment of patients with resected non–small cell lung cancer (NSCLC) without sensitizing EGFR and ALK alterations, adjuvant nivolumab does not appear to yield improvements in disease-free survival (DFS) when given after planned adjuvant chemotherapy and/or radiotherapy, according to a phase 3 study.

Adjuvant nivolumab confers no DFS benefit in resected NSCLC

17 Jun 2026

Acute-phase corticosteroid therapy linked to long COVID

15 Jun 2026 by

Among patients hospitalized with severe SARS-CoV-2 infection, acute-phase systemic corticosteroid exposure is associated with greater odds of long COVID symptoms, according to a study.

Acute-phase corticosteroid therapy linked to long COVID

15 Jun 2026

Higher arousal threshold predicts hypoxic burden in OSA

13 Jun 2026

A higher arousal threshold is associated with a more severe hypoxic burden in patients with obstructive sleep apnea (OSA) but shows a nonlinear correlation with apnea-hypopnea index (AHI), reveals a study.

Higher arousal threshold predicts hypoxic burden in OSA

13 Jun 2026

RSV tied to increased childhood asthma risk

12 Jun 2026 by

A study presented at ESPID 2026 demonstrates an association between respiratory syncytial virus (RSV) infection and an increased risk of childhood asthma.

RSV tied to increased childhood asthma risk

12 Jun 2026

Original New Drug Application Approvals by US FDA (1-15 May 2026)

12 Jun 2026

New drug applications approved by US FDA as of 1-15 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 May 2026)

12 Jun 2026

High-dose influenza vaccine linked to reduced hospitalization risk in older adults

11 Jun 2026

High-dose inactivated influenza vaccine (HD-IIV) confers improved protection against hospitalization outcomes for older adults when compared with standard-dose inactivated influenza vaccine (SD-IIV), according to the results of a meta-analysis.

High-dose influenza vaccine linked to reduced hospitalization risk in older adults

11 Jun 2026

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

11 Jun 2026 by

In the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in China, the combination of ivonescimab plus chemotherapy significantly improves overall survival (OS) compared with tislelizumab plus chemotherapy, according to the phase III HARMONi-6 trial.

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

11 Jun 2026

News & Updates

Showing Respirology articles

Showing

Specialty:

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

Fluvoxamine wins, metformin disappoints in long COVID fatigue

Fluvoxamine wins, metformin disappoints in long COVID fatigue

Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients

Reduced RT plus chemo-immunotherapy feasible in older/frail NSCLC patients

Adjuvant nivolumab confers no DFS benefit in resected NSCLC

Adjuvant nivolumab confers no DFS benefit in resected NSCLC

Acute-phase corticosteroid therapy linked to long COVID

Acute-phase corticosteroid therapy linked to long COVID

Higher arousal threshold predicts hypoxic burden in OSA

Higher arousal threshold predicts hypoxic burden in OSA

RSV tied to increased childhood asthma risk

RSV tied to increased childhood asthma risk

Original New Drug Application Approvals by US FDA (1-15 May 2026)

Original New Drug Application Approvals by US FDA (1-15 May 2026)

High-dose influenza vaccine linked to reduced hospitalization risk in older adults

High-dose influenza vaccine linked to reduced hospitalization risk in older adults

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC

Frontline ivonescimab plus chemo ups survival in advanced squamous NSCLC